---
schema_version: "secwatch.filing_event.v1"
accession: "0001607062-22-000359"
form_type: "8-K"
ticker: "RGBP"
cik: "0001589150"
company_name: "Regen BioPharma Inc"
filed_at: "2022-05-17T23:59:59+00:00"
generated_at: "2026-06-25T11:59:43.782526+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Regen Biopharma issues 100M shares to settle debt; subsidiary gets NR2F6 patent

## Summary
- Issued 100M common shares to Coventry Enterprises LLC to satisfy $334,800 of convertible debt; note balance now $648,001.
- KCL Therapeutics subsidiary awarded U.S. Patent No. 11,324,719 for small molecule NR2F6 agonists/antagonists.
- Shares issued under Section 4(a)(2) exemption without underwriters or general solicitation.

## SEC filing metadata
- accession: 0001607062-22-000359
- form_type: 8-K
- ticker: RGBP
- cik: 0001589150
- company_name: Regen BioPharma Inc
- filed_at: 2022-05-17T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 3.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1589150/000160706222000359/0001607062-22-000359-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1589150/000160706222000359/rgbp051622form8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001607062-22-000359
- JSON: https://secwatch.observer/filing/0001607062-22-000359.json
- Plain text: https://secwatch.observer/filing/0001607062-22-000359.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.